Protos considered for PBS delisting
Osteoporosis drug strontium ranelate (Protos) was almost recommended for delisting by regulators.
At its latest hearing, the Pharmaceutical Benefits Advisory Committee (PBAC) said it considered delisting the drug due to the evidence linking it’s use to an increased risk of cardiovascular events. Instead, PBAC advised its use be restricted, and moved it to second line use “where the patients is unable to use other osteoporosis treatments due to contraindication or intolerance.”
“The PBAC was of a mind to recommend the delisting of strontium under